Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Shares Outstanding (Weighted Average) (2016 - 2026)

Lexaria Bioscience's Shares Outstanding (Weighted Average) history spans 12 years, with the latest figure at $11.1 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $11.1 million for Q1 2026, up 46.69% from a year ago — trailing twelve months through Feb 2026 was $11.1 million (up 46.69% YoY), and the annual figure for FY2025 was $7.3 million, up 23.04%.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $11.1 million at Lexaria Bioscience, up from $10.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $11.1 million in Q1 2026 to a low of $2.4 million in Q1 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $5.9 million (2024), against an average of $5.7 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) plummeted 52.55% in 2022, then skyrocketed 240.51% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $6.0 million in 2022, then dropped by 6.95% to $5.5 million in 2023, then tumbled by 46.65% to $3.0 million in 2024, then skyrocketed by 240.51% to $10.1 million in 2025, then grew by 10.29% to $11.1 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $11.1 million, $10.1 million, and $7.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.